3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma
2
Leukemia, Plasma Cell
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Diseases
1
Hemangioma, Cavernous, Central Nervous System
1
Corneal Diseases
1
Blood Protein Disorders
1
Interventions
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Smoldering Multiple Myeloma
×
daratumumab
×
Clear all
NCT07393282
2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3
Not yet recruiting
270 enrolled